vTv Therapeutics (VTVT) Retained Earnings (2016 - 2025)
vTv Therapeutics (VTVT) has disclosed Retained Earnings for 11 consecutive years, with -$326.7 million as the latest value for Q4 2025.
- Quarterly Retained Earnings fell 9.0% to -$326.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$326.7 million through Dec 2025, down 9.0% year-over-year, with the annual reading at -$326.7 million for FY2025, 9.0% down from the prior year.
- Retained Earnings hit -$326.7 million in Q4 2025 for vTv Therapeutics, down from -$319.6 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of -$247.7 million in Q1 2022 to a low of -$326.7 million in Q4 2025.
- Historically, Retained Earnings has averaged -$282.1 million across 5 years, with a median of -$280.9 million in 2023.
- Biggest five-year swings in Retained Earnings: grew 14.21% in 2021 and later fell 10.86% in 2023.
- Year by year, Retained Earnings stood at -$248.8 million in 2021, then dropped by 6.71% to -$265.5 million in 2022, then fell by 5.84% to -$281.0 million in 2023, then dropped by 6.65% to -$299.7 million in 2024, then decreased by 9.0% to -$326.7 million in 2025.
- Business Quant data shows Retained Earnings for VTVT at -$326.7 million in Q4 2025, -$319.6 million in Q3 2025, and -$310.9 million in Q2 2025.